These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1606075)

  • 1. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.
    Shepherd FA; MacCormick R; Eisenhauer EA
    Ann Oncol; 1991; 2(10):772-3. PubMed ID: 1666298
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of LY 186641 in advanced renal cancer.
    Mahjoubi M; Kattan J; Bonnay M; Schmitt H; Droz JP
    Invest New Drugs; 1993 Nov; 11(4):323-8. PubMed ID: 7726992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
    Brown TD; O'Rourke TJ; Kuhn JG; Craig JB; Havlin K; Burris HA; Cagnola J; Hamilton JM; Grindey GB; Satterlee WG
    Anticancer Drugs; 1994 Apr; 5(2):151-9. PubMed ID: 8049498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of sulofenur (LY186641) in gastric cancer.
    Kamthan A; Scarffe JH; Walling J; Hatty S; Peters B; Coleman R; Smyth JF
    Anticancer Drugs; 1992 Aug; 3(4):331-5. PubMed ID: 1421428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C; Hilgendorf I; Freund M; Casper J
    Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug treatment of metastatic renal cell carcinoma].
    Rafiyan MR; Jäger E
    Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
    Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH
    Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
    Harshman L; Srinivas S
    Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 11. [An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO].
    Rexer H; Doehn C; Bedke J
    Urologe A; 2017 Jul; 56(7):928-929. PubMed ID: 28616640
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
    Talbot DC; Smith IE; Nicolson MC; Powles TJ; Button D; Walling J
    Cancer Chemother Pharmacol; 1993; 31(5):419-22. PubMed ID: 8431978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.
    O'Brien ME; Hardy J; Tan S; Walling J; Peters B; Hatty S; Wiltshaw E
    Cancer Chemother Pharmacol; 1992; 30(3):245-8. PubMed ID: 1628377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
    Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
    Piot G; Droz JP; Theodore C; Ghosn M; Rouëssé J; Amiel JL
    Oncology; 1988; 45(5):371-2. PubMed ID: 3412745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 18. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 19. Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Stoter G; Bono AV; Splinter TA; Fossa SD; Verbaeys AJ; de Mulder PH; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1249-50. PubMed ID: 2767112
    [No Abstract]   [Full Text] [Related]  

  • 20. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.